Other News To Note
Friday, March 4, 2011
Oxygen Biotherapeutics Inc., of Morrisville, N.C., received a $2.075-million, two-year grant from the U.S. Army to study its Oxycyte perfluorocarbon (PFC) emulsion as a therapeutic intervention to reduce brain damage in victims of traumatic brain injury. PFC emulsions interact with the reticuloendothelial system as part of the clearance mechanism and affect the number of circulating platelets. The preclinical studies supported by the Army grant will examine the effects of Oxycyte on the immune system, platelet function and distribution, as well as the safety and efficacy of platelet transfusion.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.